Loading organizations...
§ Private Profile · Trieste, Friuli-Venezia Giulia, Italy
AI simulation platform for drug and medical device development, using in silico modeling and virtual patients for pharma and biotech.
InSilicoTrials, based in Milan, Italy, develops an AI-powered digital simulation platform that utilizes in silico modeling and virtual patients to accelerate drug and medical device development. This platform is designed to significantly reduce R&D time and costs by up to four years, improve trial accuracy, and support regulatory compliance through the generation of digital evidence for healthcare innovations. The company integrates AI from over 70 scientific partners and FDA models, offering cloud-based simulation services primarily to the pharmaceutical and biotech sectors globally. In 2024, InSilicoTrials was recognized as AI Startup of the Year at Startup Grind Global, triumphing over 650 other contenders for its impact on R&D efficiency. The organization is led by CEO and founder Luca Emili, with Mario Torchia serving as COO, and was founded in 2018.
InSilicoTrials has raised $7.5M across 2 funding rounds.
InSilicoTrials has raised $7.5M in total across 2 funding rounds.
InSilicoTrials has raised $7.5M in total across 2 funding rounds.
InSilicoTrials's investors include Massimiliano Magrini, Pi Campus, Moonstone Venture Capital, United Ventures.
InSilicoTrials has raised $7.5M across 2 funding rounds. Most recently, it raised $3.5M Series A in July 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 27, 2020 | $3.5M Series A | Massimiliano Magrini | PI Campus | Announced |
| Jul 1, 2020 | $4M Seed | — | Moonstone Venture Capital, United Ventures | Announced |
InSilicoTrials is a health tech company developing a cloud-based AI simulation platform that predicts clinical trial outcomes for drugs and medical devices, reducing R&D time, costs, and reliance on traditional trials.[1][2][3] It serves pharmaceutical, biotech, and medical device companies by providing virtual patient models, synthetic patient populations, and advanced simulations to assess safety, efficacy, and risks across diverse therapeutic areas like osteoporosis, tuberculosis, and cardiac pathologies.[1][3][4] The platform solves the industry's high failure rates, lengthy timelines (up to 12 years and $2.6 billion per drug), and ethical concerns by enabling faster, cheaper in silico testing, with potential to cut development costs by up to 50%.[1][3]
Founded in 2017, the company has gained momentum through partnerships like the Microsoft for Startups Pegasus Program, integration with Azure Marketplace, and EU-funded projects such as In Silico World and SimCardioTest, which validate and commercialize its tools globally.[3][4]
InSilicoTrials was founded in 2017 in Trieste, Italy, by Luca Emili (CEO) and Roberta Bursi, who brought expertise in life sciences, cybersecurity, and digital innovation.[2][1] The idea emerged from frustration with drug development's inefficiencies—high costs, long timelines, and patient risks—prompting the team to build a platform revolutionizing healthcare via AI-driven simulations.[1] Early traction came from addressing these pain points, evolving into a comprehensive tool backed by academic, researcher, and regulator models; pivotal moments include leading AI simulation development in EU projects like In Silico World and SimCardioTest.[3]
InSilicoTrials rides the in silico trials wave, fueled by regulatory encouragement from agencies like the FDA and EMA for modeling to supplement traditional trials, amid digital transformation in healthcare akin to banking or entertainment.[3] Timing aligns with AI advancements, post-COVID urgency for faster therapies, and EU initiatives like In Silico World, which standardize simulations for diseases from Covid-19 to aneurysms, producing validation data and SaMD guidelines.[3] Market forces favoring it include exploding demand for cost-effective R&D (global pharma spend exceeds $200B annually), privacy regs boosting synthetic data, and cloud scalability; it influences the ecosystem by democratizing university models via cloud, accelerating adoption, and paving regulatory paths for simulation-based approvals.[1][3][4]
InSilicoTrials is poised to dominate AI-driven drug development as regulators formalize in silico standards and Azure integration scales its reach to enterprise clients.[3][4] Trends like multimodal AI, real-world evidence integration, and personalized medicine will amplify its virtual patient tech, potentially halving industry timelines further. Its influence may evolve into a de facto platform for global trials, powering safer therapies and drawing more VC/pharma partnerships—hyper-accelerating the shift from wet-lab to digital R&D.[1][3] This positions it as a cornerstone in taming biotech's high-stakes inefficiencies.